Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14593

UPID:
RFXK_HUMAN

ALTERNATIVE NAMES:
Ankyrin repeat family A protein 1; Regulatory factor X subunit B; Regulatory factor X-associated ankyrin-containing protein

ALTERNATIVE UPACC:
O14593; O95839; Q24JQ1; Q6FGA8

BACKGROUND:
The Regulatory factor X-associated ankyrin-containing protein, or RFXANK, is integral to the immune system's defense against pathogens. It regulates MHC class II gene expression, a key component in the adaptive immune response. RFXANK's ability to bind the X1 box of MHC-II promoters and potentially activate RAF1 underscores its multifaceted role in cellular regulation and immune response.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in immune response regulation, mutations in RFXANK result in Bare lymphocyte syndrome 2, highlighting the protein's therapeutic significance. Exploring RFXANK's function could lead to breakthroughs in treating immunodeficiency disorders, offering hope for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.